Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2)

Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2)

June 06, 2018 By Siyi

Review of the drugs:

Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(2)

Enbrel and Remicade have begun to suffer impacts of generic drugs, with market shares largely reducing.

As the third anti-TNFα monoclonal antibody marketed and the first fully human antibody, Humira has taken 14 clinical indications upon its advantages in clinical efficacy (the above two separately have 5 and 8) and advanced triumphantly on the market, to become a king.

FDA has approved the two biosimilars of Humira: Amgen’s Amjevita (adalimumab-atto, September 23, 2016) and Ogivri (trastuzumab-dkst, August 25, 2017), however, AbbVie managed to shut them out by reaching a settlement with Amgen and accusing Boehringer Ingelheim of patent infringement, therefore, Humira will still be unshakeable in the next years.

Although “envied” by other drugs, Humira makes a “a wry smile”: the sunset is so beautiful, but that evening (of Humira) is on the way!

Cimzia and Simponi were marketed later than the above three monoclonal antibodies, and their sales are expected to continue to rise to reach USD 2 billion before patent expiration, however, the overall market of anti-TNFα monoclonal antibodies becomes increasingly saturated and tumultuous due to impacts of generic drugs and competition from latecomers, and is difficult to continue the peak of the above 3 all exceeding USD 10 billion sales.

Marketing time

Company

Pharmaceutical product

Target

2015 sales

2016 sales

2017 sales

Trend

2002

Amgen/Pfizer/Takeda

Enbrel (etanercept)

TNFα fusion protein

88.97

88.74

80.78

-9%

2004

J & J/MSD/Mitsubishi Tanabe

Remicade (infliximab)

Anti-TNFα monoclonal antibody

83.55

82.34

77.28

-9.30%

2005

AbbVie

Humira (adalimumab)

Anti-TNFα monoclonal antibody

140.12

160.78

184.27

14.60%

2009

J & J

Simponi/Simponi Aria (golimumab)

Anti-TNFα monoclonal antibody

13.28

17.45

18.33

5.0%

2013

UCB (EUR)

Cimzia (certolizumab)

Anti-TNFα monoclonal antibody

10.83

13.07

14.24

9.0%

Related reading: Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(1)

Register as Visitor to CPhI China 2018!

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat